AN2718

• CAT Number: I002322
• CAS Number: 174672-06-1
• Molecular Formula: C7H6BClO2
• Molecular Weight: 168.383
• Purity: ≥95%
• Solubility: Soluble in DMSO
• Storage: -20°C
• IUPAC Name: 5-chloro-1-hydroxy-3H-2,1-benzoxaborole
• InChI: InChI=1S/C7H6BClO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
• InChIKey: HMAFTPZYFJFEHK-UHFFFAOYSA-N
• SMILES: B1(C2=C(CO1)C=C(C=C2)Cl)O

AN2718(CAT: I002322) is a synthetic antifungal agent that belongs to the class of boron-containing compounds known as benzoxaboroles. It is primarily used topically for the treatment of onychomycosis, a fungal infection of the nails. AN2718 works by inhibiting the fungal enzyme leucyl-tRNA synthetase, which is essential for protein synthesis in the fungus. This inhibition disrupts the growth and replication of the fungal cells, leading to their elimination. AN2718 has shown efficacy against various dermatophyte species, including Trichophyton rubrum and Trichophyton mentagrophytes, which are common causes of onychomycosis. It is usually applied as a topical solution or lacquer directly to the affected nails.

Reference

1. Expert Opin Investig Drugs. 2014 Jan;23(1):97-106. doi: 10.1517/13543784.2013.840289. Epub 2013 Sep 26.
Investigational drugs for onychomycosis.
Gupta AK(1), Simpson FC.
Author information:
(1)Department of Medicine, University of Toronto , Toronto, Ontario , Canada +1 519 657 4222 ext. 277 ; +1 519 657 4233 ; .
INTRODUCTION: Onychomycosis is the fungal infection of the nail plate by dermatophytes, yeasts and nondermatophyte molds. The treatment of onychomycosis poses many challenges due to low initial cure rates and a high rate of relapse and recurrence. Oral therapy is limited by adverse events and drug-drug interactions, whereas topical therapy has limited penetrance through the nail plate.
AREAS COVERED: New and reformulated drugs are in development for the treatment of onychomycosis. Experimental molecules include both oral and topical azole molecules, topical reformulations of terbinafine, the benzoxaboroles tavaborole and AN2718, the aganocide NVC-422 and the photosensitizer Sylsens B. These drugs are in varying stages of development so results from in vitro studies to Phase III clinical trials are discussed to present a complete picture of the current development pipeline for onychomycosis.
EXPERT OPINION: The development of new molecules from familiar and novel classes for both oral and topical administration is encouraging. It is clear that there is currently more emphasis on the development of topical drugs than orals, due to their lower potential for adverse events and drug-drug interactions. The emergence of novel molecular targets is encouraging for the possibility of combination therapy and any future drug-resistant strains of fungi.